Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Current Assets (2019 - 2026)

Alx Oncology Holdings' Current Assets history spans 5 years, with the latest figure at $188.7 million for Q4 2023.

  • On a quarterly basis, Current Assets fell 30.38% to $188.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $188.7 million, a 30.38% decrease, with the full-year FY2023 number at $188.7 million, down 30.38% from a year prior.
  • Current Assets hit $188.7 million in Q4 2023 for Alx Oncology Holdings, down from $199.1 million in the prior quarter.
  • Over the last five years, Current Assets for ALXO hit a ceiling of $436.0 million in Q4 2020 and a floor of $9.8 million in Q4 2019.
  • Historically, Current Assets has averaged $278.1 million across 5 years, with a median of $280.9 million in 2022.
  • Biggest five-year swings in Current Assets: skyrocketed 4344.82% in 2020 and later crashed 31.55% in 2023.
  • Tracing ALXO's Current Assets over 5 years: stood at $9.8 million in 2019, then skyrocketed by 4344.82% to $436.0 million in 2020, then dropped by 15.82% to $367.0 million in 2021, then fell by 26.17% to $271.0 million in 2022, then tumbled by 30.38% to $188.7 million in 2023.
  • Business Quant data shows Current Assets for ALXO at $188.7 million in Q4 2023, $199.1 million in Q3 2023, and $219.6 million in Q2 2023.